Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients.

arterial stiffness ideal cardiovascular health metrics type 2 diabetes visceral fat area

Journal

Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326

Informations de publication

Date de publication:
08 Sep 2023
Historique:
revised: 09 07 2023
received: 24 09 2022
accepted: 04 08 2023
medline: 8 9 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: aheadofprint

Résumé

"Obesity paradox" occurs in type 2 diabetes mellitus (T2DM) patients when body mass index (BMI) is applied to define obesity. We examined the association of visceral fat area (VFA) as an obesity measurement with arterial stiffness in seven ideal cardiovascular health metrics (ICVHMs). A total of 29 048 patients were included in the analysis from June 2017 to April 2021 in 10 sites of National Metabolic Management Centers. ICVHMs were modified from the recommendations of the American Heart Association. Brachial-ankle pulse wave velocity (BaPWV) ≥ 1400 cm/s was employed to evaluate increased arterial stiffness. Multivariate regression models were used to compare the different effects of BMI and VFA on arterial stiffness. Lower VFA was more strongly associated with low BaPWV than lower BMI when other ICVHMs were included (adjusted odds ratio [OR], 0.85 [95% confidence interval [CI], 0.80-0.90] vs OR 1.08 [95% CI, 1.00-1.17]). Multivariable-adjusted ORs for arterial stiffness were highest in patients with the VAT area VFA in the range of 150-200 cm In patients with T2DM, using VAT for anthropometric measures of obesity, VFA was more relevant to cardiovascular risk than BMI in the seven ICVHMs. For anthropometric measures of obesity in the ICVHMs to describe cardiovascular risk VFA would be more optimal than BMI.

Sections du résumé

BACKGROUND BACKGROUND
"Obesity paradox" occurs in type 2 diabetes mellitus (T2DM) patients when body mass index (BMI) is applied to define obesity. We examined the association of visceral fat area (VFA) as an obesity measurement with arterial stiffness in seven ideal cardiovascular health metrics (ICVHMs).
METHODS METHODS
A total of 29 048 patients were included in the analysis from June 2017 to April 2021 in 10 sites of National Metabolic Management Centers. ICVHMs were modified from the recommendations of the American Heart Association. Brachial-ankle pulse wave velocity (BaPWV) ≥ 1400 cm/s was employed to evaluate increased arterial stiffness. Multivariate regression models were used to compare the different effects of BMI and VFA on arterial stiffness.
RESULTS RESULTS
Lower VFA was more strongly associated with low BaPWV than lower BMI when other ICVHMs were included (adjusted odds ratio [OR], 0.85 [95% confidence interval [CI], 0.80-0.90] vs OR 1.08 [95% CI, 1.00-1.17]). Multivariable-adjusted ORs for arterial stiffness were highest in patients with the VAT area VFA in the range of 150-200 cm
CONCLUSION CONCLUSIONS
In patients with T2DM, using VAT for anthropometric measures of obesity, VFA was more relevant to cardiovascular risk than BMI in the seven ICVHMs. For anthropometric measures of obesity in the ICVHMs to describe cardiovascular risk VFA would be more optimal than BMI.

Identifiants

pubmed: 37680102
doi: 10.1111/1753-0407.13463
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Capacity building for multidisciplinary cooperation in diagnosis and treatment of major metabolic diseases
ID : Z155080000004
Organisme : China Health Promotion Foundation
Organisme : Chinese Academy of Engineering
ID : 2019-XZ-42
Organisme : National Key Research and Development Program of China
ID : 2016YFC0901200
Organisme : National Key Research and Development Program of China
ID : 2018YFC1311800
Organisme : National Natural Science Foundation of China
ID : 82200939
Organisme : National Natural Science Foundation of China
ID : 82201475
Organisme : Program for Shanghai Outstanding Medical Academic Leader
ID : 2019LJ07
Organisme : Yunnan Fundamental Research Projects
ID : 202201AT070242
Organisme : Yunnan Science and Technology Plan Project
ID : 202201AY070001-127

Informations de copyright

© 2023 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Références

Roth GA, Johnson C, Abajobir A, et al. Global, regional, and National Burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.
Zhang Y, Wang Y, Ning G, He P, Wang W. Protecting older people: a high priority during the COVID-19 pandemic. Lancet. 2022;400(10354):729-730.
Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
Polonsky TS, Ning H, Daviglus ML, et al. Association of Cardiovascular Health with Subclinical Disease and Incident Events: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2017;6(3):e004894.
Ford ES, Greenlund KJ, Hong Y. Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation. 2012;125(8):987-995.
Ommerborn MJ, Blackshear CT, Hickson DA, et al. Ideal cardiovascular health and incident cardiovascular events: the Jackson heart study. Am J Prev Med. 2016;51(4):502-506.
Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329-343.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163.
Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617-1624.
Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280(21):1843-1848.
Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640-1649.
Zhang Y, Wang W, Ning G. Metabolic management center: an innovation project for the management of metabolic diseases and complications in China. J Diabetes. 2019;11(1):11-13.
Wang T, Lu J, Su Q, et al. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 2019;4(9):874-883.
Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015;38(1):150-158.
Examination Committee of Criteria for ‘Obesity Disease’ in Japan. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66(11):987-992.
Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. 2021;13(4):315-409.
World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. World Health Organization; 2008.
Du H, Li L, Bennett D, et al. Fresh fruit consumption and major cardiovascular disease in China. N Engl J Med. 2016;374(14):1332-1343.
American Diabetes Association. 6. Glycemic Targets: Standards of medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.
Yamakage H, Ito R, Tochiya M, et al. The utility of dual bioelectrical impedance analysis in detecting intra-abdominal fat area in obese patients during weight reduction therapy in comparison with waist circumference and abdominal CT. Endocr J. 2014;61(8):807-819.
Wang S, Shi J, Peng Y, et al. Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-Centre study. Cardiovasc Diabetol. 2021;20(1):82.
Takashima N, Turin TC, Matsui K, et al. The relationship of brachial-ankle pulse wave velocity to future cardiovascular disease events in the general Japanese population: the Takashima study. J Hum Hypertens. 2014;28(5):323-327.
Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. Arch Intern Med. 2007;167(19):2122-2127.
Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation. 2006;114(2):160-167.
Terry DF, Pencina MJ, Vasan RS, et al. Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham heart study participants. J Am Geriatr Soc. 2005;53(11):1944-1950.
Hainer V, Aldhoon-Hainerová I. Obesity paradox does exist. Diabetes Care. 2013;36(Suppl 2):S276-S281.
Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233-244.
Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res. 1996;4(2):201-203.
Karlsson T, Rask-Andersen M, Pan G, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med. 2019;25(9):1390-1395.
Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation. 2015;132(17):1639-1647.
Liu J, Fox CS, Hickson DA, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab. 2010;95(12):5419-5426.
Schiavo L, Pilone V, Tramontano S, Rossetti G, Iannelli A. May bioelectrical impedance analysis method Be used in alternative to the dual-energy X-ray absorptiometry in the assessment of fat mass and fat-free mass in patients with obesity? Pros, cons, and perspectives. Obes Surg. 2020;30(8):3212-3215.
Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-2605.
Ohkuma T, Ninomiya T, Tomiyama H, et al. Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension. 2017;69(6):1045-1052.
Haraguchi N, Koyama T, Kuriyama N, et al. Assessment of anthropometric indices other than BMI to evaluate arterial stiffness. Hypertens Res. 2019;42(10):1599-1605.
Huang J, Chen Z, Yuan J, et al. Association between body mass index (BMI) and brachial-ankle pulse wave velocity (baPWV) in males with hypertension: a community-based cross-section study in North China. Med Sci Monit. 2019;25:5241-5257.
Tang B, Luo F, Zhao J, et al. Relationship between body mass index and arterial stiffness in a health assessment Chinese population. Medicine. 2020;99(3):e18793.
Meredith-Jones K, Taylor R, Brown R, et al. Age- and sex-specific visceral fat reference cutoffs and their association with cardio-metabolic risk. Int J Obes (Lond). 2021;45(4):808-817.
Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013;62(10):921-925.
Kammerlander AA, Lyass A, Mahoney TF, et al. Sex differences in the associations of visceral adipose tissue and Cardiometabolic and cardiovascular disease risk: the Framingham Heart Study. J Am Heart Assoc. 2021;10(11):e019968.

Auteurs

Ling Zhao (L)

Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Xiangming Zhou (X)

Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Yufei Chen (Y)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Qijuan Dong (Q)

Department of Endocrinology, People's Hospital of Zhengzhou Affiliated Henan University of Chinese Medicine, zhengzhou, China.

Qidong Zheng (Q)

Department of Internal Medicine, The Second People's Hospital of Yuhuan, Yuhuan, China.

Yufan Wang (Y)

Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Li Li (L)

Department of Endocrinology, Ningbo First Hospital, Ningbo, China.

Dong Zhao (D)

Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.

Bangqun Ji (B)

Department of Endocrinology, Xingyi People's Hospital, Xingyi, China.

Fengmei Xu (F)

Department of Endocrinology and Metabolism, Hebi Coal (group). LTD. General Hospital, Hebi, China.

Juan Shi (J)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Ying Peng (Y)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Yifei Zhang (Y)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Yuancheng Dai (Y)

Department of Internal Medicine of Traditional Chinese Medicine, Sheyang Diabetes Hospital, Yancheng, China.

Tingyu Ke (T)

Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Weiqing Wang (W)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Classifications MeSH